posted on 2021-08-05, 14:37authored byWessel
A. C. Burger, Patrick R. Gentry, Alice E. Berizzi, Ziva Vuckovic, Emma T. van der Westhuizen, Geoff Thompson, Mahmuda Yeasmin, Craig W. Lindsley, Patrick M. Sexton, Christopher J. Langmead, Andrew B. Tobin, Arthur Christopoulos, Celine Valant, David M. Thal
The
M5 muscarinic acetylcholine receptor (mAChR) has
emerged as an exciting therapeutic target for the treatment of addiction
and behavioral disorders. This has been in part due to promising preclinical
studies with the M5 mAChR selective negative allosteric
modulator (NAM), ML375. The binding site of ML375 remains unknown,
however, making it difficult to develop improved M5 mAChR
selective modulators. To determine the possible location of the ML375
binding site, we used radioligand binding and functional assays to
show that ML375 does not interact with the well-characterized “common”
mAChR allosteric site located in the receptor’s extracellular
vestibule, nor a previously proposed second allosteric site recognized
by the modulator, amiodarone. Molecular docking was used to predict
potential allosteric sites within the transmembrane (TM) domain of
the M5 mAChR. These predicted sites were assessed using
M5–M2 mAChR receptor chimeras and further
targeted with site-directed mutagenesis, which enabled the identification
of a putative binding site for ML375 at the interface of TMs 2–4.
Collectively, these results identify a third allosteric site at the
M5 mAChR and highlight the ability of allosteric modulators
to selectively target highly conserved proteins.